GLAXOSMITHKLINE PHARMACEUTICALS
Quarterly Results Analysis [Dec2023]
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹805 Cr | ₹957 Cr | ₹762 Cr | ₹787 Cr | ₹802 Cr | ₹917 Cr | ₹745 Cr | ₹810 Cr |
Expenses | ₹587 Cr | ₹668 Cr | ₹618 Cr | ₹618 Cr | ₹574 Cr | ₹660 Cr | ₹596 Cr | ₹634 Cr |
Operating Income | ₹218 Cr | ₹289 Cr | ₹144 Cr | ₹170 Cr | ₹229 Cr | ₹257 Cr | ₹149 Cr | ₹175 Cr |
Other Income | ₹28 Cr | ₹28 Cr | ₹36 Cr | ₹28 Cr | ₹23 Cr | ₹22 Cr | ₹28 Cr | ₹19 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
Depreciation | ₹17 Cr | ₹18 Cr | ₹16 Cr | ₹17 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr |
Profit Before Tax | ₹65 Cr | ₹299 Cr | ₹181 Cr | ₹190 Cr | ₹224 Cr | ₹262 Cr | ₹160 Cr | ₹208 Cr |
Profit After Tax | ₹46 Cr | ₹218 Cr | ₹132 Cr | ₹133 Cr | ₹165 Cr | ₹193 Cr | ₹116 Cr | ₹-55 Cr |
EPS | ₹2.70 | ₹12.84 | ₹7.81 | ₹7.88 | ₹9.71 | ₹11.42 | ₹7.04 | ₹71.96 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLAXOSMITHKLINE PHARMACEUTICALS | 10.5% | 3.8% | 67.8% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
CIPLA | 4.5% | -3.1% | 52.8% |
DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
MANKIND PHARMA | 2.7% | 12.4% | NA |
TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
LUPIN | 3.1% | -1.1% | 127.4% |
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -15.85 % |
Y-o-Y | 0.37 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹805 Cr | -15.85 | |
Sep2023 | ₹957 Cr | 25.65 | |
Jun2023 | ₹762 Cr | -3.28 | |
Mar2023 | ₹787 Cr | -1.85 | |
Dec2022 | ₹802 Cr | -12.50 | |
Sep2022 | ₹917 Cr | 23.05 | |
Jun2022 | ₹745 Cr | -7.97 | |
Mar2022 | ₹810 Cr | - |
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -24.67 % |
Y-o-Y | -4.65 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹218 Cr | -24.67 | |
Sep2023 | ₹289 Cr | 101.20 | |
Jun2023 | ₹144 Cr | -15.24 | |
Mar2023 | ₹170 Cr | -25.78 | |
Dec2022 | ₹229 Cr | -10.99 | |
Sep2022 | ₹257 Cr | 72.53 | |
Jun2022 | ₹149 Cr | -15.01 | |
Mar2022 | ₹175 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -10.48 % |
Y-o-Y | -5.02 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 27.08% | -10.48 | |
Sep2023 | 30.25% | 60.14 | |
Jun2023 | 18.89% | -12.38 | |
Mar2023 | 21.56% | -24.38 | |
Dec2022 | 28.51% | 1.75 | |
Sep2022 | 28.02% | 40.17 | |
Jun2022 | 19.99% | -7.62 | |
Mar2022 | 21.64% | - |
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -78.98 % |
Y-o-Y | -72.22 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹46 Cr | -78.98 | |
Sep2023 | ₹218 Cr | 64.47 | |
Jun2023 | ₹132 Cr | -0.88 | |
Mar2023 | ₹133 Cr | -18.92 | |
Dec2022 | ₹165 Cr | -14.92 | |
Sep2022 | ₹193 Cr | 66.41 | |
Jun2022 | ₹116 Cr | Positive | |
Mar2022 | ₹-55 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -75.01 % |
Y-o-Y | -72.31 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 5.68 % | -75.01 | |
Sep2023 | 22.73 % | 30.93 | |
Jun2023 | 17.36 % | 2.48 | |
Mar2023 | 16.94 % | -17.41 | |
Dec2022 | 20.51 % | -2.80 | |
Sep2022 | 21.1 % | 35.26 | |
Jun2022 | 15.6 % | Positive | |
Mar2022 | -6.75 % | - |
GLAXOSMITHKLINE PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -78.97 % |
Y-o-Y | -72.19 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹2.7 | -78.97 | |
Sep2023 | ₹12.84 | 64.40 | |
Jun2023 | ₹7.81 | -0.89 | |
Mar2023 | ₹7.88 | -18.85 | |
Dec2022 | ₹9.71 | -14.97 | |
Sep2022 | ₹11.42 | 62.22 | |
Jun2022 | ₹7.04 | -90.22 | |
Mar2022 | ₹71.96 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD